Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67.
about
Extracts from Curcuma zedoaria Inhibit Proliferation of Human Breast Cancer Cell MDA-MB-231 In Vitro.Circulating tumor cell clusters-associated gene plakoglobin is a significant prognostic predictor in patients with breast cancer.Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapyA CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancerLobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapyStromal expression of miR-21 identifies high-risk group in triple-negative breast cancer.A prognostic model for triple-negative breast cancer patients based on node status, cathepsin-D and Ki-67 index.Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) PatientsAssociations between sociodemographic and clinicopathological factors and breast cancer subtypes in a population-based study.Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registryNew insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancerThe expressions of NEDD9 and E-cadherin correlate with metastasis and poor prognosis in triple-negative breast cancer patients.Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers.New insight on the biological role of p53 protein as a tumor suppressor: re-evaluation of its clinical significance in triple-negative breast cancer.Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.The use of digital images improves reproducibility of the ki-67 labeling index as a proliferation marker in breast cancer.Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer.c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer.Expression analysis of E-cad and vascular endothelial growth factor in triple-negative breast cancer patients of different ethnic groups in western China.Expression patterns of claudins in patients with triple-negative breast cancer are associated with nodal metastasis and worse outcome.Prognostic Value of E-Cadherin and β-Catenin in Triple-Negative Breast Cancer.A meta-analysis of biomarkers for the prognosis of triple-negative breast cancer patients.An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications.Using computer assisted image analysis to determine the optimal Ki67 threshold for predicting outcome of invasive breast cancer.
P2860
Q33634352-62F6686E-C503-490A-9E8D-C200749CC089Q33668173-B6A40F5B-E840-4E95-B740-3D3DA8506A6CQ34501788-915ED890-FEC9-415F-87E1-BEB0AB26AE63Q34506546-C753D276-C3CB-41E1-BB23-E99FEA0BE4F0Q34537257-147E05E6-CDBF-467B-A527-1ED52B3B22EEQ34647811-93C5B7E4-DCDF-45DF-9FC7-133275C0E185Q35067947-D335CA9B-50DD-47F1-B199-47D7595153F5Q35651216-AF50FD5B-3E86-4C16-B8EC-5AF185B8E25DQ36235990-74F24A3D-4CD2-4F6E-9324-80A3D9695479Q36892788-FAB34EB5-F298-4EC0-969A-B7AC8046D397Q37269463-9D97E718-34BB-40D3-9CC6-5DD26AC826E3Q37283486-615FE787-9874-42D0-94AE-F10B7E7D1465Q37704344-D28D4BC5-5A83-4C4B-9B49-A3B2C14DD047Q38417021-1C83BB13-869B-42DE-849E-0578D0DB2F1EQ38647802-6FC5A658-8DA7-484B-A6A1-A566028B7ED1Q40148453-0FA9ABB6-99F5-45E0-A751-793F90BC56CBQ41588399-AC58A85A-785B-4A28-8560-E9AB91CB0B64Q42519332-1B8870EC-5175-45CA-8D23-E940043B7598Q47101001-C9DFE4AE-F1E1-49E9-9A22-57F3086B1956Q48141048-FF82C347-6B07-436C-87DD-499E93509149Q50560631-918A4F18-94C7-4B54-A598-0280BC803FC9Q51684386-B06DDEA9-AEDA-4AA5-B368-BAEE341036A0Q53111508-32F9D0C2-1672-45F2-B3B3-E54EE23475CFQ55284921-145DFF04-CE3E-4086-BC92-86419C0EF537
P2860
Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Advantages of adjuvant chemoth ...... c markers E-cadherin and Ki67.
@ast
Advantages of adjuvant chemoth ...... c markers E-cadherin and Ki67.
@en
type
label
Advantages of adjuvant chemoth ...... c markers E-cadherin and Ki67.
@ast
Advantages of adjuvant chemoth ...... c markers E-cadherin and Ki67.
@en
prefLabel
Advantages of adjuvant chemoth ...... c markers E-cadherin and Ki67.
@ast
Advantages of adjuvant chemoth ...... c markers E-cadherin and Ki67.
@en
P2093
P2860
P356
P1476
Advantages of adjuvant chemoth ...... c markers E-cadherin and Ki67.
@en
P2093
Katsumi Ikeda
Kosei Hirakawa
Masakazu Yashiro
Naoki Aomatsu
Shinichiro Kashiwagi
Tetsuro Ishikawa
Tsutomu Takashima
Yoshinari Ogawa
P2860
P2888
P356
10.1186/BCR3068
P577
2011-11-30T00:00:00Z
P5875
P6179
1017424966